ASH 2021 Conference Coverage on VuMedi

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

ASH 2021 Conference Coverage on VuMedi

Lymphoma
Leukemia
Myeloma
MDS and MPN
Benign Hematology
COVID-19 and Blood Cancers

ASH 2021 Updated Results From the Phase 3 QUAZAR AML-001 Trial: Long-Term OS With Oral Aza in AML in 1st Remission After Intensive Chemo

By ASH 2021 Conference Coverage on VuMedi FEATURING Andrew Wei

710 views

February 8, 2022

Comments 0

Leukemia

Acalabrutinib vs. Rituximab + Idelalisib/Bendamustine in R/R CLL: 3-…

ASH 2021 Conference Coverage on VuMedi

P. Ghia

124 views

ASH 2021 Updated Results From the Phase 3 QUAZAR AML-001 Trial: Long…

ASH 2021 Conference Coverage on VuMedi

A. Wei

710 views

ASH 2021 Updates on Asciminib vs. Investigator-Selected TKI in Newly…

ASH 2021 Conference Coverage on VuMedi

J. Cortés

114 views

ASH 2021 Highlights on ALLG Phase 2 INTERVENE Study: Investigating N…

ASH 2021 Conference Coverage on VuMedi

C. Chua

19 views

ASH 2021 Results From the SEQUOIA Study: Zanubrutinib vs. Bendamusti…

ASH 2021 Conference Coverage on VuMedi

C. Tam

113 views

ASH 2021 on a Study of Venetoclax and Low Dose Ara-C (VALDAC) to Tar…

ASH 2021 Conference Coverage on VuMedi

T. Ing Soo

15 views

ASH 2021 Long Term Follow-Up and Combined Phase 2 Results of Eprenet…

ASH 2021 Conference Coverage on VuMedi

D. Sallman

83 views

ASH 2021 MRD Assessment in CLL

ASH 2021 Conference Coverage on VuMedi

P. Ghia

385 views

ASH 2021 Update on the Safety & Efficacy of Menin Inhibition in MLL-…

ASH 2021 Conference Coverage on VuMedi

E. Stein

130 views

ASH 2021 Clinical Predictors of Outcomes in Adult Acute Leukemias an…

ASH 2021 Conference Coverage on VuMedi

P. Desai

281 views

ASH 2021: Comparing Outcomes Between CPX-351 and HMA+Ven As 1L Thera…

ASH 2021 Conference Coverage on VuMedi

P. Desai

102 views

ASH 2021 on Older Patients With AML: So I Am in Remission - Now What?

ASH 2021 Conference Coverage on VuMedi

P. Desai

518 views

ASH 2021: Outcomes of Patients Treated With CPX-351 as 1L Therapy fo…

ASH 2021 Conference Coverage on VuMedi

A. Jain

12 views

ASH 2021 Updates on Efficacy and AE Management of BTKi in CLL/SLL

ASH 2021 Conference Coverage on VuMedi

J. Rhodes

252 views

ASH 2021 Updates on Novel Advances in AML Therapy

ASH 2021 Conference Coverage on VuMedi

E. Wang

227 views

ASH 2021 Updates on Therapy of p53 Mutant Hematologic Malignancies

ASH 2021 Conference Coverage on VuMedi

M. Davids

228 views

ASH 2021 Update on BOVen in CLL: Early MRD Kinetics Define a High-Ri…

ASH 2021 Conference Coverage on VuMedi

J. Soumerai

34 views

ASH 2021 Update on MRD in ALL: Standard of Care & Areas for Further …

ASH 2021 Conference Coverage on VuMedi

L. Muffly

454 views

ASH 2021 MRD Directed Therapy: A New Frontier in AML

ASH 2021 Conference Coverage on VuMedi

A. Wei

445 views